Cantor Fitzgerald initiated coverage on Surgery Partners with a new price target
$SGRY
Hospital/Nursing Management
Health Care
Cantor Fitzgerald initiated coverage of Surgery Partners with a rating of Overweight and set a new price target of $43.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/14/2024 | $38.00 | Buy | UBS |
| 10/11/2024 | Sector Weight | KeyBanc Capital Markets | |
| 6/28/2024 | $31.00 | Outperform | Macquarie |
| 3/6/2024 | $35.00 | Equal Weight | Barclays |
| 11/14/2023 | $39.00 → $35.00 | Market Perform → Outperform | TD Cowen |
| 6/2/2023 | $42.00 → $45.00 | Neutral → Buy | BofA Securities |
| 5/12/2023 | $48.00 | Buy | Mizuho |
| 4/21/2023 | $43.00 | Overweight | Cantor Fitzgerald |
These eleven mid-cap stocks were the best performers in the last week. Are they in your portfolio? Virtu Financial, Inc. (NASDAQ:VIRT) shares jumped 30.04% after reporting better-than-expected Q2 financial results. V.F. Corporation (NYSE:VFC) stock upped 22.38% after the company announced it entered into a Stock and Asset Purchase Agreement to sell its Supreme brand to EssilorLuxottica (OTC: ESLOF) for $1.5 billion in cash. Several analysts raised their price forecasts on VFC. New Fortress Energy Inc. (NASDAQ:NFE) shares grew 20.19% after the company announced that it achieved First LNG for its initial Fast LNG asset located offshore Altamira, Mexico. Riot Platforms Inc (NASDAQ:
BRENTWOOD, Tenn., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, today announced results for the third quarter ended September 30, 2024. Revenues increased 14.3% to $770.4 million compared to the prior year period Same-facility revenues increased 4.2%Same-facility cases increased 3.7% Net loss attributable to Surgery Partners, Inc. was $31.7 million Adjusted EBITDA was $128.6 million, representing 21.9% growth compared to the prior year period Adjusted EBITDA margin was 16.7%, expanding 100 basis points from the prior year periodFull year 2024 revenue and Adjusted EBIT
BRENTWOOD, Tenn., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, announced the Company will release its third quarter 2024 results before the market opens on Tuesday, November 12, 2024, to be followed by a conference call at 8:30 a.m. (Eastern Time). You can join the call as follows: Dial in number for live access: 1-877-451-6152 (domestic), 1-201-389-0879 (international)Replay (available 3 hours after the call and available until November 26, 2024): 1-844-512-2921 (domestic), 1-412-317-6671 (international)Passcode for the live call and the replay: 13749078 Intereste
BRENTWOOD, Tenn., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, today announced results for the second quarter ended June 30, 2024. Revenues increased 14.2% to $762.1 million compared to the prior year period Same-facility revenues increased 9.9%Same-facility cases increased 3.9% Net loss attributable to Surgery Partners, Inc. was $15.5 million Adjusted EBITDA was $118.3 million, representing 18.1% growth compared to the prior year period Adjusted EBITDA margin was 15.5%, expanding 50 basis points from the prior year periodFull year guidance raised to greater than $3.
10-Q - Surgery Partners, Inc. (0001638833) (Filer)
8-K - Surgery Partners, Inc. (0001638833) (Filer)
10-Q - Surgery Partners, Inc. (0001638833) (Filer)
SC 13G/A - Surgery Partners, Inc. (0001638833) (Subject)
SC 13G - Surgery Partners, Inc. (0001638833) (Subject)
SC 13G/A - Surgery Partners, Inc. (0001638833) (Subject)
UBS initiated coverage of Surgery Partners with a rating of Buy and set a new price target of $38.00
KeyBanc Capital Markets initiated coverage of Surgery Partners with a rating of Sector Weight
Macquarie initiated coverage of Surgery Partners with a rating of Outperform and set a new price target of $31.00
4 - Surgery Partners, Inc. (0001638833) (Issuer)
4 - Surgery Partners, Inc. (0001638833) (Issuer)
3 - Surgery Partners, Inc. (0001638833) (Issuer)
BRENTWOOD, Tenn., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, today announced results for the third quarter ended September 30, 2024. Revenues increased 14.3% to $770.4 million compared to the prior year period Same-facility revenues increased 4.2%Same-facility cases increased 3.7% Net loss attributable to Surgery Partners, Inc. was $31.7 million Adjusted EBITDA was $128.6 million, representing 21.9% growth compared to the prior year period Adjusted EBITDA margin was 16.7%, expanding 100 basis points from the prior year periodFull year 2024 revenue and Adjusted EBIT
BRENTWOOD, Tenn., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, announced the Company will release its third quarter 2024 results before the market opens on Tuesday, November 12, 2024, to be followed by a conference call at 8:30 a.m. (Eastern Time). You can join the call as follows: Dial in number for live access: 1-877-451-6152 (domestic), 1-201-389-0879 (international)Replay (available 3 hours after the call and available until November 26, 2024): 1-844-512-2921 (domestic), 1-412-317-6671 (international)Passcode for the live call and the replay: 13749078 Intereste
BRENTWOOD, Tenn., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, today announced results for the second quarter ended June 30, 2024. Revenues increased 14.2% to $762.1 million compared to the prior year period Same-facility revenues increased 9.9%Same-facility cases increased 3.9% Net loss attributable to Surgery Partners, Inc. was $15.5 million Adjusted EBITDA was $118.3 million, representing 18.1% growth compared to the prior year period Adjusted EBITDA margin was 15.5%, expanding 50 basis points from the prior year periodFull year guidance raised to greater than $3.
PURCHASE, NY, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE:TDOC), the global leader in whole-person virtual care, today appointed Eric Evans to the company's board of directors. Mr. Evans, currently chief executive officer and director of Brentwood, TN-based Surgery Partners, Inc. (NASDAQ:SGRY), is a recognized healthcare and hospital executive with significant experience leading complex organizations operating at the intersection of care and technology. Mr. Evans joins the board following the retirement of Senator William Frist, M.D. earlier this year, and will serve on the board's compensation committee. David B. Snow, Jr., non-executive Chairman of the company's board,
PLANTATION, Fla., Aug. 12, 2022 /PRNewswire/ - Akumin Inc. (NASDAQ:AKU) (TSX:AKU) ("Akumin" or the "Company") provided a business update and announced the termination of employment of its Chief Financial Officer, William Larkin and the appointment of David Kretschmer as Interim Chief Financial Officer, effective today. The Company has implemented a transformation program with initiatives focused on its operations, growth, and capital. These initiatives are intended to support the Company's objectives with respect to patient access and experience, customer and partner engagement, financial sustainability, and employee well-being. The Company is receiving support from a globally recognized tr
BRENTWOOD, Tenn., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Members of management of Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, will be meeting with investors today, January 10, 2022, as part of the 40th Annual J.P. Morgan Healthcare Conference, including a virtual presentation at 5:15 p.m. ET. Based on results through November 2021, the Company is re-affirming its 2021 Adjusted EBITDA guidance of $325 million to $330 million and its 2021 Revenue guidance of 19% to 21% growth over 2020 results. The Company completed the deployment of approximately $185 million of capital in three acquisitions in December 20